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Background: The purpose of this paper was to demonstrate the use of an online service for
conducting a systematic review and meta-analysis of the efficacy of topical prostaglandin analogs
in reducing intraocular pressure (IOP) in glaucoma and ocular hypertension.
Methods: An online service provider (Doctor Evidence) reviewed and extracted data from the
peer-reviewed literature through September 2009. Randomized controlled studies of at least
three months’ duration assessing at least two prostaglandin analogs in patients with primary
open-angle glaucoma, ocular hypertension, or normal-tension glaucoma were included. The
primary endpoint was mean IOP. Summary estimates were created using random-effects models.
The Q Chi-square test was used to assess statistical heterogeneity.
Results: Sixteen studies satisfied the inclusion criteria and were analyzed. On average, greater
IOP-lowering was seen with bimatoprost relative to latanoprost (1 mmHg, P = 0.025) and travoprost (0.8 mmHg, P = 0.033) based on mean IOP after 12–26 weeks of treatment. No statistical
difference was observed in IOP-lowering between latanoprost and travoprost (P = 0.841). Findings
were similar to previously published meta-analyses of topical prostaglandin analogs.
Conclusion: Systematic reviews relying on meta-analytic techniques to create summary
statistics are considered to be the “gold standard” for synthesizing evidence to support clinical
decision-making. However, the process is time-consuming, labor-intensive, and outside the
capability of most formulary managers. We have demonstrated the effectiveness of a commercial
service that facilitates the process of conducting such reviews.
Keywords: evidence-based medicine, meta-analysis, review, systematic, prostaglandin analogs,
glaucoma
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Evidence-based formulary decisions require systematic review of the peer-reviewed
medical literature and meta-analysis to pool data across clinical studies. This type of
data review and analysis is time-consuming, labor-intensive, and requires specialized statistical expertise, putting such work outside the capability of most formulary
managers. Furthermore, the dynamic nature of the medical literature means that today’s
systematic review, which required months and considerable resources to complete,
may be outdated within weeks of completion.
Use of a web-based provider of systematic review services and analysis software
may ease the process of developing systematic reviews and meta-analyses, and thus
facilitate the critical appraisal of current data for evidence-based formulary decisions.
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One such service provider, Doctor Evidence (Doctor Evidence
LLC, Santa Monica, CA), builds evidence databases from
clinical studies on a web-based platform. Tools available
on the platform allow users to identify and pool individual
studies by participant or study characteristics and to select
the outcome measures to be analyzed. Details and results

of individual studies, as well as results of meta-analysis of
pooled data across studies, can be viewed. The data collection
and analysis are transparent, and the collated data are presented
in a way that is easily readable, as shown in Figure 1.
In collaboration with the Doctor Evidence service
p rovider, we performed a systematic review of the

Table 1 Studies analyzed
Study

Study design

Duration of
follow-up

Study population

Prostaglandin analog study arms
(n = number of patients included
in analysis)

Alagoz et al4

Single-site RCT

180 days

Bimatoprost 0.03% QD (n = 36)
Travoprost 0.004% QD (n = 46)

Arcieri et al5

Single-site RCT

6 months

Cantor et al6

Multicenter RCT

6 months

Cantor et al7

Single-site RCT

6 months

Cardascia et al8

Single-site RCT

180 days

Dirks et al9

Multicenter RCT

3 months

Gandolfi et al10

Multicenter RCT

3 months

a

Halpern et al11

Multi-center RCT

48 weeks

Kammer et al12

Multicenter RCT

3 months

Koz et al13

Single-site RCT

6 months

Netland et al14

Multicenter RCT

1 year

Noecker et al15

Multicenter RCT

6 months

Noecker et al16

Multicenter RCT

3 months

Noecker et al17

Multicenter RCT

3 months

Parrish et al18

Multicenter RCT

12 weeks

Adult patients with newly
diagnosed glaucoma, visual field
defects, and IOP $22 mmHg
Adult patients with POAG,
pseudophakic glaucoma, or aphakic
glaucoma who needed lower IOP
Adult patients with POAG or
OHT and IOP 21–34 mmHg
after washout
Adult patients with POAG or
OHT and IOP 21–34 mmHg
after washout
POAG patients ages 40–60 years
with visual field loss and untreated
IOP . 20 mmHg
Adult patients with normal-tension
glaucoma who needed IOPlowering therapy
Adult patients with glaucoma or
OHT and IOP 22–34 mmHg
after washout
Black patients with POAG or
glaucoma and IOP 21–36 mmHg
Adult patients with glaucoma or
OHT who had inadequate IOP
control on latanoprost monotherapy
Previously untreated adult patients with
POAG or OHT and IOP
22–36 mmHg
Adults with open-angle glaucoma
or OHT and IOP 24–36 mmHg
Adults with glaucoma and/or OHT
and IOP 22–34 mmHg after washout
Black adult patients with POAG
or OHT and IOP 22–34 mmHg
after washout
Black adult patients with POAG
or OHT and IOP 22–34 mmHg
after washout
Adult patients with glaucoma or OHT
and IOP $ 23 mmHg after washout

Varma et al19

Multicenter RCT

12 weeks

b

Adult patients with glaucoma or OHT
and IOP $ 23 mmHg after washout

Bimatoprost 0.03% QD (n = 16)
Latanoprost 0.005% QD (n = 15)
Travoprost 0.004% QD (n = 17)
Bimatoprost 0.03% QD (n = 76)
Travoprost 0.004% QD (n = 81)
Bimatoprost 0.03% QD (n = 14)
Travoprost 0.004% QD (n = 12)
Latanoprost 0.005% QD (n = 9)
Travoprost 0.004% QD (n = 9)
Bimatoprost 0.03% QD (n = 33)
Latanoprost 0.005% QD (n = 27)
Bimatoprost 0.03% QD (n = 109)
Latanoprost 0.005% QD (n = 105)
Latanoprost 0.005% QD (n = 43)
Travoprost 0.004% QD (n = 49)
Bimatoprost 0.03% QD (n = 128)
Travoprost 0.004% QD (n = 132)
Bimatoprost 0.03% QD (n = 20)
Latanoprost 0.005% QD (n = 20)
Travoprost 0.004% QD (n = 20)
Latanoprost 0.005% QD (n = 196)
Travoprost 0.004% QD (n = 200)
Bimatoprost 0.03% QD (n = 133)
Latanoprost 0.005% QD (n = 136)
Bimatoprost 0.03% QD (n = 49)
Travoprost 0.004% QD (n = 45)
Bimatoprost 0.03% QD (n = 16)
Travoprost 0.004% QD (n = 15)
Bimatoprost 0.03% QD (n = 136)
Latanoprost 0.005% QD (n = 136)
Travoprost 0.004% QD (n = 138)
Bimatoprost 0.03% (n = 137)
Latanoprost 0.005% (n = 136)
Travoprost 0.004% (n = 138)

Notes: aSubgroup analysis of Netland 2001study; bSupplementary analysis of study by Parrish et al.18
Abbreviations: RCT, randomized controlled trial; IOP, intraocular pressure; QD, once daily; POAG, primary open-angle glaucoma; OHT, ocular hypertension.
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Table 2 Reasons for exclusion of studies from the analyses shown
Study

Reason

Cantor et al7

• Missing error measurement needed for inclusion
in meta-analysis of mean IOP
• Missing change in diurnal IOP data needed for
inclusion in analysis of change in diurnal IOP
from baseline
• Missing mean IOP data from a study visit after
12–26 weeks of treatment that would be needed
for inclusion in meta-analysis of mean IOP
• Missing change in diurnal IOP data needed for
inclusion in analysis of change in diurnal IOP
from baseline
• Missing error measurement needed for inclusion
in meta-analysis of mean IOP
• Missing change in diurnal IOP data needed for
inclusion in analysis of change in diurnal IOP
from baseline
• Missing error measurement needed for inclusion
in meta-analysis of mean IOP
• Missing diurnal IOP measurements needed for
inclusion in analysis of change in diurnal IOP
from baseline
• Missing error measurement needed for inclusion
in meta-analysis of mean IOP
• Missing diurnal IOP measurements needed for
inclusion in analysis of change in diurnal IOP
from baseline
• This paper reports the same patients/data as
Parrish 2003, so it could not be included as an
independent data source for the same analyses

Halpern et al11

Netland et al14

Noecker et al17

Noecker et al16

Varma et al19

peer-reviewed literature to determine the relative efficacy
of the prostaglandin analogs bimatoprost, latanoprost,
and travoprost in lowering intraocular pressure (IOP) in
primary open-angle glaucoma (POAG), normal-tension glaucoma, and ocular hypertension. We present the results here to
demonstrate the utility and value of this web-based tool for
conducting a meta-analysis, leading to efficient development
of a systematic review.

Methods
Creation of an evidence database
using the online platform
Relevant studies were identified by the service provider
through an independent search of the Cochrane Library
(CDSR, CENTRAL, DARE), Medline, and published systematic reviews. The search used the terms “glaucoma”,
“primary”, “open-angle”, “POAG”, “intraocular pressure”,
“ocular”, “eye”, “pressure”, “hypertension”, “hypertensive”,
“IOP”, “normotensive”, “normal tension”, “low tension”,
“bimatoprost”, “Lumigan”, “latanoprost”, “Xalatan”,
“travoprost”, “Travatan”, “prostaglandin analogs”, and

Therapeutics and Clinical Risk Management 2011:7

“visual field”, and was last updated in September 2009.
A priori criteria for study inclusion in the database were:
• Randomized controlled trial with head-to-head comparison
of at least two of the following interventions: bimatoprost
0.03% (Lumigan®, Allergan Inc, Irvine, CA), latanoprost
0.005% (Xalatan®, Pfizer Inc, New York, NY), and
travoprost 0.004% (Travatan ®, Alcon Laboratories,
Fort Worth, TX) used as monotherapy in patients with
glaucoma or ocular hypertension
• Mean IOP and/or mean IOP fluctuation reported
• Minimum follow-up of 12 weeks
• At least 50% of the study population comprised of patients
diagnosed with POAG, ocular hypertension, or normaltension glaucoma, with the rest of the study population
diagnosed with any type of glaucoma
• Study published in English.
Data collection followed a standard procedure used by
the service provider. Briefly, two evidence-based medical
specialists read each paper completely and extracted data,
including the study design, patient characteristics, clinical outcomes, and statistical data. The extracted data were
imported into a template that was subsequently evaluated
by proprietary technologies and processes for discrepancies,
such as mismatches of subgroup and total population data.
A third evidence-based medical specialist then performed
an additional quality check of the data and reconciled any
discrepancies identified prior to final approval of each study
imported into the comprehensive database.

Systematic data review and meta-analysis
Application layers on the database platform permitted review
of the patient characteristics and outcomes of individual studies as well as results of meta-analyses of pooled data. The
primary analyses of mean IOP and mean reduction in IOP
from baseline were based on data from the earliest time point
of IOP measurement (typically between 8 am and 10 am) on
the latest study visit within the timeframe of 12 weeks to six
months of follow-up. The reduction in diurnal IOP from baseline was also analyzed based on the latest study visit within
the timeframe of 12 weeks to six months of follow-up, with
diurnal IOP defined as the average of IOP measurements taken
at two or more time points during the day. Other outcomes
data, including responder rates and achievement of target pressure levels, were also included in the database in the event that
researchers decided to analyze additional endpoints.
Meta-analyses used the inverse variance method of
weighting data for pooling.1 Heterogeneity of results across
studies was tested with the Cochrane Q Chi-square test.2
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Random-effects models were used for analyses because of
the heterogeneity of treatment effects across studies.3

Results
The literature search identified 260 studies that were
potentially relevant for inclusion in the database. Of these
studies, 242 were rejected because they did not meet
the inclusion criteria (reasons included not being a clinical
study [n = 23], not being a head-to-head randomized controlled
trial [n = 32], a crossover rather than parallel-group study
design [n = 7], less than half of the population diagnosed with
POAG, ocular hypertension, or normal-tension glaucoma
[n = 53], did not compare at least two of the following:

bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%
as monotherapy [n = 110], mean IOP or mean IOP fluctuation
not reported [n = 7], inadequate follow-up period [n = 8], not in
English [n = 1], and meeting abstract with insufficient information available [n = 1]). The remaining 18 studies were randomized controlled studies comparing the prostaglandin analogs.
These studies satisfied the inclusion criteria and were assigned
for data extraction. Two of these 18 studies were rejected from
the evidence database, one because there were discrepancies
in the manuscript and no author clarification was received, and
the other because outcomes were stratified by race rather than
by treatment. The remaining 16 studies4–19 were included in the
evidence database and analyzed.

Bimatoprost vs Latanoprost
Gandolfi 2001

−0.3 (−1.13 to 0.53)

Koz 2007

−2.5 (−3.68 to −1.32)

Noecker 2003

−1.5 (−2.31 to −0.69)

Parrish 2003

−0.1 (−0.86 to 0.66)

Arcieri 2005

−0.6 (−1.98 to 0.78)

Overall

−0.96 (−1.8 to −0.12)
−6

−4

−2

0

2

Mean difference in IOP in mmHg (95% Cl)
(Bimatoprost minus Latanoprost)

Bimatoprost vs Travoprost
Koz 2007

−2.6 (−3.58 to −1.62)

Alagoz 2008

0 (−1.02 to 1.02)

Cantor 2006

−1.2 (−2.22 to −0.18)

Parrish 2003

−0.6 (−1.43 to 0.23)

Arcieri 2005

0.1 (−1.28 to 1.48)

Kammer 2010

−0.5 (−1.27 to 0.27)

Overall

−0.82 (−1.58 to −0.07)
−6

−4

−2

0

2

Mean difference in IOP in mmHg (95% Cl)
(Bimatoprost minus Travoprost)

Latanoprost vs Travoprost
Koz 2007

−0.1 (−1.44 to 1.24)

Arcieri 2005

0.7 (−0.51 to 1.91)

Parrish 2003

−0.5 (−1.31 to 0.31)

Cardascia 2003

0.4 (−1.16 to 1.96)
−0.06 (−0.62 to 0.50)

Overall
−3

−2

−1

0

1

2

Mean difference in IOP in mmHg (95% Cl)
(Latanoprost minus Travoprost)
Figure 1 Forest plots of the differences in intraocular pressure between prostaglandin analogs in individual studies and in the meta-analyses of the pooled data.
Abbreviation: IOP, intraocular pressure.
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Details of these 16 studies, including the study design,
study duration, study population, and drugs tested, are listed
in Table 1. Data were available from more of these studies
for the primary outcomes chosen for analysis, ie, mean IOP
and mean change in diurnal IOP from baseline, than for other
efficacy outcomes that might be of interest, such as responder
rates or achievement of target pressure levels, which could
also be analyzed using the database. Of the 16 studies, several
were not included in either of the meta-analyses presented
because they did not report data for the primary outcomes, or
data were reported without standard deviations or other error
measurements. The specific reasons for studies not being
included in the analyses shown are listed in Table 2.
Differences in mean IOP between the prostaglandin
analogs were evaluated by meta-analysis (Figure 1). The
effects of bimatoprost and latanoprost on mean IOP in the
morning after 12–26 weeks of treatment were compared in
826 patients in five studies.5,10,13,15,18 The results demonstrated
substantial heterogeneity across studies (Q = 15.6, P = 0.004).
Meta-analysis of the data showed that mean IOP was 1 mmHg
lower with bimatoprost than with latanoprost (mean difference −0.96 mmHg, 95% confidence interval [CI] −1.8,
−0.12, P = 0.025). Six studies that reported mean data with
estimates of variance compared the effects of bimatoprost and
travoprost on mean IOP in the morning after 12–26 weeks
of treatment.4–6,12,13,18 Data were available from a total of
846 patients treated with bimatoprost or travoprost in these
studies. Meta-analysis of the data showed that mean IOP was
0.8 mmHg lower with bimatoprost than with travoprost (mean
difference −0.82 mmHg, 95% CI −1.58, −0.07, P = 0.033).
The effects of latanoprost and travoprost on mean IOP in
the morning after 12–26 weeks of treatment were compared
in 364 patients in four studies.5,8,13,18 Meta-analysis of the
data showed no statistically significant difference in mean
IOP between latanoprost and travoprost (mean difference
−0.06 mmHg, 95% CI −0.62, 0.50, P = 0.841).
The effects of bimatoprost and latanoprost on the change
in diurnal IOP from baseline after 12–26 weeks of treatment
were compared in two studies,9,18 but pooling of the data was
not possible because no estimate of variance was reported in
one of the studies.9 In the study reported by Parrish et al,18
the mean reduction in diurnal IOP from baseline at week 12
was 0.3 mmHg larger with bimatoprost than with latanoprost
(n = 273, Figure 2), while in the study reported by Dirks et al,9
the mean reduction in diurnal IOP from baseline at week 13
was 1.1 mmHg larger with bimatoprost than with latanoprost
(n = 60, P = 0.035, Figure 2). Differences in results between
the studies may reflect differences in the patient populations

Therapeutics and Clinical Risk Management 2011:7
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and their treatment history. Patients in the study reported by
Dirks et al9 were diagnosed with normal-tension glaucoma,
while patients in the study reported by Parrish et al18 were
diagnosed with ocular hypertension or glaucoma associated
with elevated IOP. Half of the patients enrolled in the study
reported by Parrish et al18 were being treated with latanoprost
when they were screened for study entry. The treatment
history of patients enrolled in the study by Dirks et al9 was
not reported.
The effects of bimatoprost and travoprost on the change
in diurnal IOP from baseline after 12–26 weeks of treatment were compared in 534 patients in two studies.12,18
Meta-analysis of the data showed that the mean reduction in
diurnal IOP from baseline was 0.7 mmHg larger in patients
treated with bimatoprost than in patients treated with travoprost (mean difference −0.66 mmHg, 95% CI −1.13, −0.19,
P = 0.006, Figure 3).
Only the study reported by Parrish et al18 compared the
effects of latanoprost and travoprost on the change in diurnal
IOP from baseline after 12–26 weeks of treatment. In that
study, the mean reduction in diurnal IOP from baseline at
week 12 was 0.3 mmHg larger with latanoprost than with
travoprost (n = 274, Figure 4).

Discussion
Clinical and formulary decision-making should be based
on the highest quality of evidence available with respect to
the effectiveness of treatment and product differentiation.
Systematic reviews of drug efficacy are useful for qualitative evaluation of study results and differences in drug
efficacy. Quantitative evaluation of differences in drug
efficacy requires meta-analysis of the pooled data with
associated statistics. There is strong evidence that lower IOP
improves outcomes for patients with glaucoma and ocular
hypertension.20–22 Conduct of a systematic review and metaanalysis using a web-based platform provided evidence that
use of bimatoprost achieved approximately a 1 mmHg lower
mean IOP compared with latanoprost or travoprost and that
this difference was statistically significant. There was no
statistically significant difference between latanoprost and
travoprost in mean IOP. These findings are consistent with
previously published meta-analyses of the efficacy of the
prostaglandin analogs.23,24 Changes in diurnal IOP from
baseline were reported in fewer studies, and meta-analysis
was possible only for the comparison of bimatoprost and
travoprost. Nonetheless, the results were consistent with
greater IOP-lowering of bimatoprost compared with latanoprost or travoprost.
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Bimatoprost
(n = 33)

Latanoprost
(n = 136)

0

Mean change in diurnal IOP from
baseline at week 13 (mmHg)

Mean change in diurnal IOP from
baseline at week 12 (mmHg)

Bimatoprost
(n = 137)

−2

−4

−6

−8

−7.0 mmHg

−7.3 mmHg

Latanoprost
(n = 27)

0

−2

−4
−2.3 mmHg
−6
−3.4 mmHg
−8

P value not reported

P < 0.05

Parrish 200318

Dirks 20069

Figure 2 Mean change in diurnal intraocular pressure from baseline in individual studies comparing bimatoprost with latanoprost.
Abbreviation: IOP, intraocular pressure.

The meta-analysis previously reported by Aptel et al24
evaluated change from baseline IOP rather than mean IOP,
and at least 90% of the patients in each included study had
to be diagnosed with POAG or ocular hypertension. The
analysis was similar to ours in that it included only studies
comparing at least two prostaglandin analogs, with a total
of eight studies involving 1608 patients included. Two of
the studies in the meta-analysis by Aptel et al were excluded
from our meta-analysis of mean IOP because their duration
was only one month, and we required a study duration of at
least 12 weeks because latanoprost may not reach full effect
after one month of treatment.25 Another two studies included
in their meta-analysis14,17 were included in our database, but
not our meta-analysis, because no error measurements were
reported (Aptel et al calculated estimates of standard deviations for their analysis). In addition to four shared studies,

our meta-analysis of mean IOP included five additional
recent studies for a total of nine studies, with data analyzed
for 1518 patients. Despite these differences, comparable
conclusions were drawn. Aptel et al reported larger reductions in IOP from baseline at 8 am in bimatoprost-treated
eyes than with latanoprost or travoprost, and we similarly
reported lower IOP with bimatoprost than with latanoprost
or travoprost at the earliest time point in the day. In addition,
both Aptel et al and our group found no significant difference
in efficacy between latanoprost and travoprost.
In our systematic review of IOP-lowering with the prostaglandin analogs, the service provider entered all available
data from the included studies into individual data templates.
For each outcome measure evaluated, the results of each
individual study could be visualized, and a summary statement of the results was provided. When meta-analysis was

Bimatoprost vs Travoprost
Parrish 2003

−0.6 (−1.36 to 0.16)

Kammer 2010

−0.7 (−1.3 to −0.1)

Overall

−0.66 (−1.13 to −0.19)

−2.5

−2

−1.5

−1

−0.5

0

0.5

Mean difference in change from baseline IOP in mmHg
(95% Cl) (Bimatoprost minus travoprost)
Figure 3 Forest plot of the difference in the change in diurnal intraocular pressure from baseline between bimatoprost and travoprost in individual studies and in the metaanalysis of the pooled data.
Abbreviation: IOP, intraocular pressure.
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0

Latanoprost
(n = 136)

Travoprost
(n = 138)

−2

−4

−6
−7.0 mmHg
−8

−6.7 mmHg

P value not reported

Parrish 2003

18

Figure 4 Mean change in diurnal intraocular pressure (IOP) from baseline in a single
study comparing latanoprost with travoprost.

possible, the meta-analysis results could also be visualized,
and a summary statement was provided.
A fixed-effect model of meta-analysis is based on a mathematical assumption that every study is evaluating a common
treatment effect. The summary treatment effect estimate
resulting from this method of meta-analysis is the “true” or
“fixed” treatment effect, and the CI describes the uncertainty
of the estimate. Often, this underlying assumption may not be
correct, because variation in study results is greater than would
be expected by chance, indicating important underlying differences in study populations or methods. When this is the case, an
alternative approach to meta-analysis is to use a random-effects
model. The random-effects model assumes that the treatment
effects in the individual studies may be different from each other,
and the most common random-effects model also assumes that
these different effects are normally distributed. Therefore, the
meta-analysis estimates the mean and standard deviation of
the different treatment effects. In our study, Chi-square tests
indicated heterogeneity of treatment effects across studies, so
random-effects models were used for meta-analysis.
Doctor Evidence, the online provider used in this report,
uses traditional (and standard) meta-analysis methods and
statistics, but the web-based platform offers three key advantages over traditional systematic reviews and meta-analysis.
First, the process of performing meta-analysis is standardized,
and the software provides an appropriate type of analysis for
the data. For example, the meta-analysis of IOP-lowering with
the prostaglandin analogs used random-effects rather than
fixed-effects meta-analysis models because of the heterogeneity of treatment effects across studies. Second, details of the
studies and analysis used are transparent. The calculations
Therapeutics and Clinical Risk Management 2011:7

used in the statistical models are provided. Third, the results
can be rapidly updated with new evidence. The database can
be updated and meta-analysis results made available within
48 hours of publication of a new study.
The service is not without cost and may exceed the
budget of an individual medical researcher, but could be
within a departmental budget. Users such as managed care
formulary managers who need to repeat meta-analyses
when new clinical data become available may realize cost
savings over the long term because of the ability to update
the database and meta-analysis rapidly. There is also a
learning curve in becoming adept at navigating the database
and accessing all the information and analyses contained
on the platform. Nonetheless, formulary managers and others may find the online service to be a useful tool, because
it facilitates the process of and shortens the timeline for
performing systematic reviews and meta-analyses. The
software provided can be used for meta-analysis of any
endpoint and allows rapid modification of the analysis to
facilitate critical appraisal of the evidence. For example,
it is possible to select and deselect studies for inclusion in
the analysis, which may be useful if, for example, there is a
desire to limit the analysis to studies with study populations
most similar to the patient population of interest.
In summary, transparent evidence-based decisions
require the use of systematic reviews for evidence synthesis.
We have demonstrated that collaboration with an online provider of systematic review services and software facilitates
the process of developing up-to-date systematic reviews and
meta-analysis of clinical evidence. Both the collection and
the analysis of the data are transparent, and the analysis can
be rapidly updated to include new evidence. The systematic
review of prostaglandin analog efficacy in glaucoma and
ocular hypertension performed in collaboration with the
web-based service provider showed that bimatoprost has
greater IOP-lowering efficacy than latanoprost or travoprost,
consistent with results of previous meta-analyses of clinical
trial data. These results demonstrate that the online service
may be a valuable tool for generating systematic reviews and
meta-analysis useful in formulary decision-making.

Acknowledgments
Allergan Inc provided funding for the systematic review and
meta-analysis. Kate Ivins, PhD, provided medical writing
assistance in the development of the manuscript.

Disclosure
CB, JMW, and DAH are employees of Allergan Inc. TF is the
Chief Medical Officer of Doctor Evidence LLC.
submit your manuscript | www.dovepress.com

Dovepress

289

Dovepress

Kymes et al

References

1. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Generality of
the basic inverse-variance method. In: Introduction to Meta-Analysis.
Chichester, UK: John Wiley & Sons, Ltd; 2009.
2. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J.
Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol
Methods. 2006;11(2):193–206.
3. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin
Trials. 1986;7(3):177–188.
4. Alagoz G, Gürel K, Bayer A, Serin D, Celebi S, Kukner S. A comparative study of bimatoprost and travoprost: Effect on intraocular
pressure and ocular circulation in newly diagnosed glaucoma patients.
Ophthalmologica. 2008;222(2):88–95.
5. Arcieri ES, Santana A, Rocha FN, Guapo GL, Costa VP. Blood-aqueous
barrier changes after the use of prostaglandin analogues in patients
with pseudophakia and aphakia: A 6-month randomized trial. Arch
Ophthalmol. 2005;123(2):186–192.
6. Cantor LB, Hoop J, Morgan L, WuDunn D, Catoira Y. BimatoprostTravoprost Study Group. Intraocular pressure-lowering efficacy of
bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma
or ocular hypertension. Br J Ophthalmol. 2006;90(11):1370–1373.
7. Cantor LB, WuDunn D, Cortes A, Hoop J, Knotts S. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients
with glaucoma or ocular hypertension. Surv Ophthalmol. 2004;49
Suppl 1:S12–S18.
8. Cardascia N, Vetrugno M, Trabucco T, Cantatore F, Sborgia C. Effects
of travoprost eye drops on intraocular pressure and pulsatile ocular
blood flow: A 180-day, randomized, double-masked comparison with
latanoprost eye drops in patients with open-angle glaucoma. Curr Ther
Res. 2003;64(7):389–400.
9. Dirks MS, Noecker RJ, Earl M, Roh S, Silverstein SM, Williams RD.
A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma. Adv
Ther. 2006;23(3):385–394.
10. Gandolfi S, Simmons ST, Sturm R, Chen K, VanDenburgh AM;
Bimatoprost Study Group 3. Three-month comparison of bimatoprost
and latanoprost in patients with glaucoma and ocular hypertension. Adv
Ther. 2001;18(3):110–121.
11. Halpern MT, Covert DW, Robin AL. Projected impact of travoprost
versus both timolol and latanoprost on visual field deficit progression
and costs among black glaucoma subjects. Trans Am Ophthalmol Soc.
2002;100:109–117.
12. Kammer JA, Katzman B, Ackerman SL, Hollander DA. Efficacy and
tolerability of bimatoprost versus travoprost in patients previously on
latanoprost: A 3-month, randomised, masked-evaluator, multicentre
study. Br J Ophthalmol. 2010;94(1):74–79.

13. Koz OG, Ozsoy A, Yarangumeli A, Kose SK, Kural G. Comparison of the
effects of travoprost, latanoprost and bimatoprost on ocular circulation: A
6-month clinical trial. Acta Ophthalmol Scand. 2007;85(8): 838–843.
14. Netland PA, Landry T, Sullivan EK, et al; Travoprost Study Group.
Travoprost compared with latanoprost and timolol in patients with
open-angle glaucoma or ocular hypertension. Am J Ophthalmol.
2001;132(4):472–484.
15. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL,
Whitcup SM; Bimatoprost/Latanoprost Study Group. A six-month
randomized clinical trial comparing the intraocular pressure-lowering
efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135(1):55–63.
16. Noecker RJ, Earl ML, Mundorf TK, Silverstein SM, Phillips MP.
Comparing bimatoprost and travoprost in black Americans. Curr Med
Res Opin. 2006;22(11):2175–2180.
17. Noecker RJ, Earl ML, Mundorf T, Peace J, Williams RD. Bimatoprost
0.03% versus travoprost 0.004% in black Americans with glaucoma or
ocular hypertension. Adv Ther. 2003;20(2):121–128.
18. Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison
of latanoprost, bimatoprost, and travoprost in patients with elevated
intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135(5):688–703.
19. Varma R, Hwang LJ, Grunden JW, Bean GW. Inter-visit intraocular pressure range: An alternative parameter for assessing intraocular pressure
control in clinical trials. Am J Ophthalmol. 2008;145(2):336–342.
20. AGIS Investigators. The Advanced Glaucoma Intervention Study
(AGIS): 7. The relationship between control of intraocular pressure and
visual field deterioration. Am J Ophthalmol. 2000;130(4):429–440.
21. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M;
Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure
and glaucoma progression: Results from the Early Manifest Glaucoma
Trial. Arch Ophthalmol. 2002;120(10):1268–1279.
22. Chauhan BC, Mikelberg FS, Balaszi AG, LeBlanc RP, Lesk M,
Trope GE. Canadian Glaucoma Study: 2. Risk factors for the progression
of open-angle glaucoma. Arch Ophthalmol. 2008;126(8):1030–1036.
23. Van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins
MH. Intraocular pressure-lowering effects of all commonly used glaucoma
drugs: A meta-analysis of randomized clinical trials. Ophthalmology.
2005;112(7):1177–1185.
24. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: A meta-analysis of randomized controlled clinical trials.
J Glaucoma. 2008;17(8):667–673.
25. Camras CB. Comparison of latanoprost and timolol in patients with
ocular hypertension and glaucoma: A six-month masked, multicenter
trial in the United States. The United States Latanoprost Study Group.
Ophthalmology. 1996;103(1):138–147.

Dovepress

Therapeutics and Clinical Risk Management

Publish your work in this journal
Therapeutics and Clinical Risk Management is an international, peerreviewed journal of clinical therapeutics and risk management, focusing
on concise rapid reporting of clinical studies in all therapeutic areas,
outcomes, safety, and programs for the effective, safe, and sustained
use of medicines. This journal is indexed on PubMed Central, CAS,

EMBase, Scopus and the Elsevier Bibliographic databases. The
manuscript management system is completely online and includes a
very quick and fair peer-review system, which is all easy to use. Visit
http://www.dovepress.com/testimonials.php to read real quotes from
published authors.

Submit your manuscript here: http://www.dovepress.com/therapeutics-and-clinical-risk-management-journal

290

submit your manuscript | www.dovepress.com

Dovepress

Therapeutics and Clinical Risk Management 2011:7

